Product Description
Mechanisms of Action: DNA Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Clavis Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Pancreatic Cancer|Adenocarcinoma
Phase 1: Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CO-101-011 | P1 |
Terminated |
Non-Small-Cell Lung Cancer |
2013-05-01 |
|
| CP4126-201 | P2 |
Completed |
Adenocarcinoma|Pancreatic Cancer |
2011-06-01 |
|
| CP4126-201 | P2 |
Terminated |
Pancreatic Cancer |
2010-07-09 |
|
| CP4126-111 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2010-04-01 |